|
1
|
Chen JF, Hsia KC, Kuo YW, Chen SH, Huang YY, Li CM, Hsu YC, Tsai SY, Ho HH. Safety Assessment and Probiotic Potential Comparison of Bifidobacterium longum subsp. infantis BLI-02, Lactobacillus plantarum LPL28, Lactobacillus acidophilus TYCA06, and Lactobacillus paracasei ET-66. Nutrients 2023; 16:126. [PMID: 38201957 PMCID: PMC10780348 DOI: 10.3390/nu16010126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 12/25/2023] [Accepted: 12/28/2023] [Indexed: 01/12/2024] Open
Abstract
Bifidobacterium longum subsp. infantis BLI-02, Lactobacillus paracasei ET-66, Lactobacillus plantarum LPL28, and Lactobacillus acidophilus TYCA06, isolated from healthy breast milk, miso, and the healthy human gut, were assessed for safety in this study. BLI-02, LPL28, TYCA06, and ET-66 exhibited no antibiotic resistance and mutagenic activity in the Ames test at the highest dosage (5000 μg/plate). No genotoxicity was observed in micronucleus and chromosomal aberration assays in rodent spermatogonia at the maximum dosage of 10 g/kg body weight (BW). No acute and sub-chronic toxicity occurred in mice and rats at the maximum tested dosage of 10 g/kg BW and 1.5 g/kg BW, respectively. The lyophilized powder of these strains survived a low pH and high bile salt environment, adhering strongly to Caco-2 cells. Unique antimicrobial activities were noted in these strains, with BLI-02 demonstrating the best growth inhibition against Vibrio parahaemolyticus, LPL28 exhibiting the best growth inhibition against Helicobacter pylori, and ET-66 showing the best growth inhibition against Aggregatibacter actinomycetemcomitans. Based on the present study, the lyophilized powder of these four strains appears to be a safe probiotic supplement at tested dosages. It should be applicable for clinical or healthcare applications.
Collapse
Affiliation(s)
- Jui-Fen Chen
- Research Product Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan; (J.-F.C.); (K.-C.H.); (Y.-Y.H.); (C.-M.L.); (Y.-C.H.); (S.-Y.T.)
| | - Ko-Chiang Hsia
- Research Product Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan; (J.-F.C.); (K.-C.H.); (Y.-Y.H.); (C.-M.L.); (Y.-C.H.); (S.-Y.T.)
| | - Yi-Wei Kuo
- Functional Investigation Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan;
| | - Shu-Hui Chen
- Process Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan;
| | - Yen-Yu Huang
- Research Product Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan; (J.-F.C.); (K.-C.H.); (Y.-Y.H.); (C.-M.L.); (Y.-C.H.); (S.-Y.T.)
| | - Ching-Min Li
- Research Product Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan; (J.-F.C.); (K.-C.H.); (Y.-Y.H.); (C.-M.L.); (Y.-C.H.); (S.-Y.T.)
| | - Yu-Chieh Hsu
- Research Product Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan; (J.-F.C.); (K.-C.H.); (Y.-Y.H.); (C.-M.L.); (Y.-C.H.); (S.-Y.T.)
| | - Shin-Yu Tsai
- Research Product Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan; (J.-F.C.); (K.-C.H.); (Y.-Y.H.); (C.-M.L.); (Y.-C.H.); (S.-Y.T.)
| | - Hsieh-Hsun Ho
- Research Product Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan; (J.-F.C.); (K.-C.H.); (Y.-Y.H.); (C.-M.L.); (Y.-C.H.); (S.-Y.T.)
- Functional Investigation Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan;
- Process Department, R&D Center, Glac Biotech Co., Ltd., Tainan City 744, Taiwan;
| |
Collapse
|